Today: 29 June 2026
Browse Category

NASDAQ:CGC 7 November 2025 - 24 December 2025

Canopy Growth (CGC) Stock on Dec. 24, 2025: Schedule III Executive Order, MTL Cannabis Deal, and the Latest Forecasts

Canopy Growth (CGC) Stock on Dec. 24, 2025: Schedule III Executive Order, MTL Cannabis Deal, and the Latest Forecasts

Canopy Growth shares closed at $1.40 on Dec. 23, up 6.06%, after heavy trading and sharp swings throughout December. The volatility followed a Dec. 18 White House executive order directing marijuana rescheduling from Schedule I to III. Trading volume spiked to over 216 million shares on Dec. 18, with implied volatility near 143%. U.S. exchanges operated a shortened session on Dec. 24.
24 December 2025
····
Tilray Stock Surges as Trump Schedule III Buzz Collides With New Vape Launch and Reverse Split Fallout

Tilray Stock Surges as Trump Schedule III Buzz Collides With New Vape Launch and Reverse Split Fallout

Tilray Brands shares surged December 15 as global cannabis stocks rallied on reports that Donald Trump may push to reclassify marijuana as a Schedule III drug. The move, which would ease federal restrictions but stop short of legalization, fueled investor optimism over potential tax and banking benefits for the industry. Tilray also completed a 1-for-10 reverse stock split and reported momentum in its Canadian portfolio.
15 December 2025
····
Canopy Growth Corporation Stock (CGC) Surges on Trump Marijuana Rescheduling Reports: Latest News, Forecasts, and What Comes Next (Dec. 15, 2025)

Canopy Growth Corporation Stock (CGC) Surges on Trump Marijuana Rescheduling Reports: Latest News, Forecasts, and What Comes Next (Dec. 15, 2025)

Canopy Growth shares surged as much as 17.9% in early European trading Monday, extending Friday’s 54% jump, after reports that President Trump may reclassify marijuana as a Schedule III drug. Trading volume spiked, with speculation focused on potential U.S. federal reform and its impact on cannabis industry taxes. No final decision has been confirmed by the White House.
15 December 2025
··
Top Stock Gainers Today (Dec. 12, 2025, 12:30 p.m. ET): cbdMD, Canopy Growth, Tilray Lead a Cannabis-Fueled Rally

Top Stock Gainers Today (Dec. 12, 2025, 12:30 p.m. ET): cbdMD, Canopy Growth, Tilray Lead a Cannabis-Fueled Rally

cbdMD (YCBD) surged 126.6% to $1.43 by 12:30 p.m. ET, leading US stock gainers amid reports President Trump may ease federal marijuana restrictions. Major indexes fell, with the S&P 500 down 1.05% and Nasdaq 100 off 1.8%. Small-cap and cannabis stocks outperformed on policy speculation and company news.
12 December 2025
····
Canopy Growth Corporation Stock (CGC) Jumps on Trump Marijuana Rescheduling Report — News, Forecasts, and What Investors Are Watching (Dec. 12, 2025)

Canopy Growth Corporation Stock (CGC) Jumps on Trump Marijuana Rescheduling Report — News, Forecasts, and What Investors Are Watching (Dec. 12, 2025)

Canopy Growth shares jumped about 21% in premarket trading Friday after reports said President Trump is expected to direct federal agencies to reclassify marijuana as a Schedule III drug. The move, first reported by the Washington Post and cited by Reuters, triggered a surge across US-listed cannabis stocks. No final decision has been made, according to a White House official.
12 December 2025
····
Canopy Growth (CGC) Stock Outlook December 2025: Debt Prepayment, Lawsuit Pressure and a High‑Risk Turnaround

Canopy Growth (CGC) Stock Outlook December 2025: Debt Prepayment, Lawsuit Pressure and a High‑Risk Turnaround

Canopy Growth shares closed at $1.15 on December 5, down 4.96%, but remain up about 13–14% over the last 10 sessions. Q2 FY2026 net revenue rose 6% to C$66.7 million, with gross margin improving to 33%. Net loss narrowed sharply to C$1.6 million from C$131.6 million a year earlier. The company ended the quarter with C$298 million in cash, exceeding its total debt.
6 December 2025
··
Canopy Growth (CGC) Lifts ‘Going Concern’ Doubts as Cash Tops Debt; Q2 FY2026 Shows 30% Canada Adult‑Use Growth

Canopy Growth (CGC) Lifts ‘Going Concern’ Doubts as Cash Tops Debt; Q2 FY2026 Shows 30% Canada Adult‑Use Growth

Canopy Growth reported Q2 FY2026 net revenue of C$66.7 million, up 6% year over year, and ended the quarter with C$298 million in cash, exceeding total debt by C$70 million. The company lifted its going-concern warning. Shares rose as much as 19% premarket before turning volatile. Operating loss narrowed to C$17 million, down 63% from a year ago.
7 November 2025
·

Stock Market Today

  • Tracker Funds Outperform Active Managers with Lower Costs, High Diversification
    June 29, 2026, 2:19 AM EDT. Tracker funds, also known as passive funds, have outperformed actively managed funds consistently over the past decade, according to AJ Bell's report. These funds mirror market indices like the FTSE 100 or S&P 500, offering diversification by investing across all companies in the index. Unlike active funds, which require fund managers to pick stocks, trackers reduce costs by eliminating management fees. Only 29% of active managers outperformed trackers in 2025. The approach, championed by Vanguard founder Jack Bogle, is summarized as "buy the haystack, not the needle." Trackers typically weight holdings by market capitalization, and come in structures such as exchange-traded funds (ETFs) or open-ended investment companies (OEICs), making them a favored choice for new and cost-conscious investors.

Latest articles

Trump-era loan caps could open door for private lenders in grad school market

Trump-era loan caps could open door for private lenders in grad school market

29 June 2026
July 1 federal loan caps slash Grad PLUS access, forcing many graduate and professional students to seek private loans; Sallie Mae projects up to 70% origination growth over several years, while SoFi reports record student-loan volume—investors now face a real-time test of how much demand shifts to private lenders as federal limits hit.
IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

29 June 2026
IREN Limited (NASDAQ:IREN) plunged 21.3% to $47.21 over five straight down days despite announcing a record $50M+ annual Warriors jersey deal, as investors focused on the company’s not fully contracted $4.4B target ARR and high short interest at 19.74% of float, with Friday’s close near the lowest analyst target.
Go toTop